{
    "clinical_study": {
        "@rank": "78837", 
        "arm_group": [
            {
                "arm_group_label": "532nm KTP laser", 
                "arm_group_type": "Other", 
                "description": "Cutera ExcelV 532nm KTP laser"
            }, 
            {
                "arm_group_label": "595nm PDL", 
                "arm_group_type": "Active Comparator", 
                "description": "Cynosure Cynergy 595nm pulsed-dye laser"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of the 532nm potassium\n      titanyl phosphate (KTP) laser in comparison with the 595nm pulsed-dye laser (PDL) for the\n      treatment of fresh surgical scars."
        }, 
        "brief_title": "Pilot Study of a Novel 532nm KTP Laser for the Treatment of Fresh Surgical Scars", 
        "condition": [
            "Scar", 
            "Surgical Scar", 
            "Cicatrix", 
            "Cicatrix, Hypertrophic", 
            "Keloid"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypertrophy", 
                "Keloid", 
                "Cicatrix, Hypertrophic", 
                "Cicatrix"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Fitzpatrick Skin Type I - IV\n\n          -  Has postoperative linear scar(s) which is one to twelve months post-surgery.\n\n          -  Having one scar that measures a minimum of 5 cm in length or two scars (bilateral)\n             each measure a minimum of 2 cm in length.\n\n          -  Be in good health.\n\n          -  Must agree not to undergo any other procedure for the treatment of scar during the\n             study.\n\n          -  Willing to refrain from excess sun exposure and willing to wear sunscreen on the\n             treated scar during the study (including the follow-up period).\n\n          -  Post-menopausal or surgically sterilized, or using a medically acceptable form of\n             birth control at least 3 months prior to enrollment and during the entire course of\n             the study.\n\n        Exclusion Criteria:\n\n          -  Participation in a study of another device or drug within 6 months prior to\n             enrollment or during the study.\n\n          -  Having received any prior treatment for the target surgical scar.\n\n          -  Pregnant and/or breastfeeding.\n\n          -  Significant concurrent illness, malignant tumors in the target area, acute or chronic\n             skin infection/inflammation, currently using immunosuppressive medications or\n             currently undergoing systemic chemotherapy.\n\n          -  Current use of any medication known to increase sensitivity to light or taking\n             prescription anticoagulation medication.\n\n          -  History of abnormal or delayed wound healing, keloid formation or pigmentary\n             disorders, particularly tendency for hyper- or hypo-pigmentation.\n\n          -  History of malignant skin disease, immune deficiency disorders, seizure disorders due\n             to light, or diseases stimulated by heat, unless prophylactic measures taken prior to\n             treatment.\n\n          -  Systemic use of isotretinoin within 6 months or corticosteroids within 12 months of\n             study participation.\n\n          -  Anytime in life, had used gold therapy (gold salts) for disorders such as\n             rheumatologic disease or lupus.\n\n          -  Current smoker or history of smoking within 12 months of study participation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01789346", 
            "org_study_id": "C-12-EV3"
        }, 
        "intervention": [
            {
                "arm_group_label": "532nm KTP laser", 
                "intervention_name": "532nm potassium titanyl phosphate (KTP) laser", 
                "intervention_type": "Device", 
                "other_name": [
                    "ExcelV laser", 
                    "Cutera ExcelV", 
                    "Excel V"
                ]
            }, 
            {
                "arm_group_label": "595nm PDL", 
                "intervention_name": "595nm pulsed-dye laser (PDL)", 
                "intervention_type": "Device", 
                "other_name": [
                    "Cynosure Cynergy", 
                    "Cynergy laser"
                ]
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Scar", 
            "Scars", 
            "Surgical Scar", 
            "Surgical Scars", 
            "Cicatrix", 
            "Hypertrophic Cicatrix", 
            "Keloid", 
            "Hypertrophic Scar", 
            "Surgical Incision", 
            "Scarring", 
            "Abdominoplasty", 
            "Tummy Tuck", 
            "Augmentation Mammoplasty", 
            "Breast Augmentation", 
            "Thyroidectomy"
        ], 
        "lastchanged_date": "December 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Washington", 
                    "country": "United States", 
                    "state": "District of Columbia", 
                    "zip": "20005"
                }, 
                "name": "Washington Institute of Dermatologic Laser Surgery"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Comparison of percentage improvement in surgical scar between treatment (532nm KTP laser) and active control (595nm PDL) treatment arms.", 
            "safety_issue": "No", 
            "time_frame": "12-weeks post-final laser treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01789346"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Cutera Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cutera Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}